newsfilter
← Latest News
Business Wire·

enGene Reports First Quarter 2025 Financial Results and Provides Business Update

Additional preliminary data from ongoing LEGEND study of detalimogene in BCG-unresponsive NMIBC with CIS, including pivotal cohort, anticipated in 2H 2025 Biologics License Application (BLA) filing planned for mid-2026